TR201905226T4 - Bir gecikmeli salım ilaç formülasyonu. - Google Patents

Bir gecikmeli salım ilaç formülasyonu. Download PDF

Info

Publication number
TR201905226T4
TR201905226T4 TR2019/05226T TR201905226T TR201905226T4 TR 201905226 T4 TR201905226 T4 TR 201905226T4 TR 2019/05226 T TR2019/05226 T TR 2019/05226T TR 201905226 T TR201905226 T TR 201905226T TR 201905226 T4 TR201905226 T4 TR 201905226T4
Authority
TR
Turkey
Prior art keywords
delayed release
drug formulation
release drug
drug
relates
Prior art date
Application number
TR2019/05226T
Other languages
English (en)
Inventor
Carlos Bravo González Roberto
Buser Thomas
Jean-Claude Goutte Frédéric
Abdul Basit Waseh
José Felipe Varum Oliveria
Ana Freire Cristina
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201905226(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of TR201905226T4 publication Critical patent/TR201905226T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Mevcut buluş, bir ilaç ve bir gecikmeli salım kaplaması içeren bir çekirdeğe sahip bir gecikmeli salım formülasyonu ile ilgilidir. Özellikle, bir ilacı kolona teslim etmek için bir gecikmeli salım formülasyonu ile ilgilidir.
TR2019/05226T 2012-04-30 2013-04-29 Bir gecikmeli salım ilaç formülasyonu. TR201905226T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261640217P 2012-04-30 2012-04-30
EP12166110.2A EP2659881B1 (en) 2012-04-30 2012-04-30 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
TR201905226T4 true TR201905226T4 (tr) 2019-05-21

Family

ID=46025554

Family Applications (3)

Application Number Title Priority Date Filing Date
TR2019/05226T TR201905226T4 (tr) 2012-04-30 2013-04-29 Bir gecikmeli salım ilaç formülasyonu.
TR2018/09416T TR201809416T4 (tr) 2012-04-30 2013-04-29 Bir gecikmeli salım ilaç formülasyonu.
TR2019/03569T TR201903569T4 (tr) 2012-04-30 2013-04-29 Bir gecikmeli salım ilaç formülasyonu.

Family Applications After (2)

Application Number Title Priority Date Filing Date
TR2018/09416T TR201809416T4 (tr) 2012-04-30 2013-04-29 Bir gecikmeli salım ilaç formülasyonu.
TR2019/03569T TR201903569T4 (tr) 2012-04-30 2013-04-29 Bir gecikmeli salım ilaç formülasyonu.

Country Status (40)

Country Link
US (6) US9364440B2 (tr)
EP (6) EP2659881B1 (tr)
JP (2) JP6621662B2 (tr)
KR (6) KR20200075024A (tr)
CN (5) CN106983735A (tr)
AR (1) AR090898A1 (tr)
AU (4) AU2013255914B2 (tr)
BR (3) BR112014026933B1 (tr)
CA (4) CA3052460C (tr)
CL (2) CL2014002796A1 (tr)
CO (2) CO7141433A2 (tr)
CR (4) CR20190246A (tr)
CU (1) CU24304B1 (tr)
CY (4) CY1120215T1 (tr)
DK (5) DK2659881T3 (tr)
EA (2) EA032811B1 (tr)
ES (5) ES2655622T3 (tr)
GE (4) GEP201706759B (tr)
HR (2) HRP20180068T1 (tr)
HU (5) HUE036187T2 (tr)
JO (6) JOP20200144A1 (tr)
LT (5) LT2659881T (tr)
ME (2) ME03641B (tr)
MX (3) MX362529B (tr)
MY (3) MY169161A (tr)
NO (1) NO2659881T3 (tr)
NZ (3) NZ629262A (tr)
PE (3) PE20150129A1 (tr)
PH (2) PH12014502339A1 (tr)
PL (5) PL2659881T3 (tr)
PT (5) PT2659881T (tr)
RS (5) RS56839B1 (tr)
SA (2) SA115370043B1 (tr)
SG (2) SG11201406799XA (tr)
SI (5) SI2659881T1 (tr)
TN (2) TN2014000442A1 (tr)
TR (3) TR201905226T4 (tr)
TW (3) TWI618547B (tr)
UY (1) UY34772A (tr)
WO (2) WO2013164316A1 (tr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2659881T1 (en) * 2012-04-30 2018-03-30 Tillotts Pharma Ag Formulation of the delayed release medicinal product
CU24343B1 (es) * 2012-04-30 2018-05-08 Tillotts Pharma Ag Formulación de fármaco de liberación retardada
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
NZ711201A (en) * 2013-02-22 2019-10-25 Zeria Pharm Co Ltd Enteric coated tablet
EP3062776A1 (en) 2013-10-29 2016-09-07 Tillotts Pharma AG A delayed release drug formulation
US10517869B2 (en) 2013-12-24 2019-12-31 Sentiss Pharma Private Limited Topical brimonidine tartrate ophthalmic solution
CN107921073B (zh) 2015-06-01 2022-10-18 塞诺生物科学股份有限公司 用于调节肠道微生物群及管理体重的方法和组合物
JP6830671B6 (ja) 2015-09-23 2021-03-10 エックスダブリューファルマ リミテッド γ−ヒドロキシ酪酸（ＧＨＢ）のプロドラッグ、その組成物および使用
CN105816883B (zh) * 2016-02-03 2018-12-14 华南师范大学 一种负载抗癌药物姜黄素的益生菌叶酸靶向载体及其制备方法
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
CN110520111B (zh) * 2016-11-30 2023-12-19 塞诺生物科学股份有限公司 用以管理体重和调节肠道微生物群的药物制剂和方法
WO2019183208A1 (en) * 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
JP2021523931A (ja) * 2018-03-23 2021-09-09 パラティン テクノロジーズ， インコーポレイテッド メラノコルチン受容体特異的ペプチド製剤及び消化管特異的送達方法
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662901A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662902A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662898A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
DK3666262T3 (da) * 2018-12-10 2022-01-31 Aphaia Ip Ag Farmaceutiske orale doseringsformer til behandling af stofskifteforstyrrelser og lignende sygdomme ved orkestreret frigivelse af enterokiner
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
CA3148226A1 (en) * 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
US20230301927A1 (en) * 2019-11-13 2023-09-28 Ethypharm Process for producing an orally administered pharmaceutical composition with colonic delivery
FR3102931B1 (fr) * 2019-11-13 2021-12-24 Ethypharm Sa Procédé de fabrication d’une composition pharmaceutique à administration orale et à délivrance colonique
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111567678A (zh) * 2020-05-11 2020-08-25 四川英格瑞生物科技有限公司 无抗畜类肠道保健剂及其制备方法
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291419A (en) * 1976-01-28 1977-08-01 Fuji Yakuhin Kogyo Kk Coloring image forming photosensitive sheet
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE4217920C2 (de) * 1992-05-30 1996-05-09 Goldwell Gmbh Verfahren zur Herstellung von pulverförmigen Mitteln zum Blondieren von menschlichen Haaren
WO1994010983A1 (en) * 1992-11-06 1994-05-26 Hisamitsu Pharmaceutical Co., Inc. Peroral pharmaceutical preparation releasable in lower digestive tract
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
CA2236605A1 (en) * 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ES2198872T3 (es) * 1999-12-16 2004-02-01 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Preparaciones farmaceuticas multiunitarias gastrorresistentes que contienen piroxicam.
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780A (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US6939920B2 (en) 2001-01-08 2005-09-06 The Goodyear Tire & Rubber Company Tire sidewall compounds having improved flex fatigue and tread compound having improved tear strength
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
JP4365106B2 (ja) 2001-05-25 2009-11-18 エスエス製薬株式会社 医薬配合剤
US7183321B2 (en) 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
WO2004110345A2 (en) * 2002-10-29 2004-12-23 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
WO2005092297A2 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1904039A2 (en) 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP4984695B2 (ja) 2006-07-11 2012-07-25 株式会社明電舎 色素増感型太陽電池及びその製造方法
SK287622B6 (sk) * 2006-07-25 2011-04-05 Peter Pap Odkladacia schránka
WO2008020286A2 (en) 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
EP2097067A2 (en) * 2006-12-05 2009-09-09 University Of The Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
EP2143424A4 (en) * 2007-03-26 2013-07-31 Teikoku Seiyaku Kk ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
BRPI0721654B8 (pt) 2007-05-07 2022-07-05 Evonik Roehm Gmbh formas de dosagem sólida compreendendo um revestimento entérico com liberação acelerada do fármaco, seu método de fabricação e uso
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
EP3698781A1 (en) 2009-06-15 2020-08-26 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid for treating myocardial infarction in a subject on concomitant statin therapy
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
US20130259947A1 (en) 2010-11-29 2013-10-03 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
CA2885680C (en) 2011-09-07 2022-10-04 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal.
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
SI2659881T1 (en) 2012-04-30 2018-03-30 Tillotts Pharma Ag Formulation of the delayed release medicinal product
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool
EP3062776A1 (en) * 2013-10-29 2016-09-07 Tillotts Pharma AG A delayed release drug formulation

Also Published As

Publication number Publication date
JP6621661B2 (ja) 2019-12-18
US20170266117A1 (en) 2017-09-21
CU20140123A7 (es) 2015-02-26
EA201491783A1 (ru) 2014-12-30
BR112014026935A2 (pt) 2017-06-27
CA2871017A1 (en) 2013-11-07
CN110237056B (zh) 2022-03-08
JP6621662B2 (ja) 2019-12-18
RS56839B1 (sr) 2018-04-30
GEP201706758B (en) 2017-10-25
SI3189830T1 (en) 2018-08-31
DK2659881T3 (en) 2018-02-05
AU2017210571A1 (en) 2017-08-24
MX366677B (es) 2019-07-19
TWI700102B (zh) 2020-08-01
EP2844222A1 (en) 2015-03-11
LT2659881T (lt) 2018-02-12
PT2659881T (pt) 2018-01-29
US9364440B2 (en) 2016-06-14
LT2844220T (lt) 2019-04-10
JP2015515964A (ja) 2015-06-04
AU2017210577B2 (en) 2018-11-29
KR20190127986A (ko) 2019-11-13
PL2844222T3 (pl) 2020-03-31
JP2015515965A (ja) 2015-06-04
CR20190245A (es) 2019-07-29
US10272048B2 (en) 2019-04-30
SG11201406798WA (en) 2014-11-27
KR20200075024A (ko) 2020-06-25
AU2013255914B2 (en) 2017-08-31
NZ629262A (en) 2017-01-27
EP2844220A1 (en) 2015-03-11
HUE043238T2 (hu) 2019-08-28
CY1122475T1 (el) 2021-01-27
JOP20200145A1 (ar) 2022-10-30
NZ725409A (en) 2018-05-25
HUE046628T2 (hu) 2020-03-30
LT3189830T (lt) 2018-07-10
SG11201406799XA (en) 2014-11-27
BR122019022551B1 (pt) 2022-07-19
SI2844222T1 (sl) 2020-02-28
MX362529B (es) 2019-01-23
PE20142442A1 (es) 2015-01-28
EA032811B1 (ru) 2019-07-31
RS58735B1 (sr) 2019-06-28
EP2659881A1 (en) 2013-11-06
US20150132380A1 (en) 2015-05-14
AU2013255913A1 (en) 2014-11-13
LT2844222T (lt) 2019-12-27
JO3574B1 (ar) 2020-07-05
KR20150004911A (ko) 2015-01-13
AU2017210571B2 (en) 2018-11-29
DK3189830T3 (en) 2018-07-16
CY1120492T1 (el) 2019-07-10
DK2844222T3 (da) 2019-12-09
CR20140485A (es) 2015-01-19
ES2655622T3 (es) 2018-02-20
PT3189830T (pt) 2018-10-19
GEP201706759B (en) 2017-10-25
JOP20200148A1 (ar) 2022-10-30
HRP20180965T1 (hr) 2018-08-10
US9814681B2 (en) 2017-11-14
AU2013255914A1 (en) 2014-11-13
AU2013255913B2 (en) 2017-08-31
KR20190127984A (ko) 2019-11-13
CN104271113B (zh) 2019-03-22
CR20140486A (es) 2015-01-19
MX2014012888A (es) 2015-04-13
MY169088A (en) 2019-02-15
EP3189830A1 (en) 2017-07-12
WO2013164316A1 (en) 2013-11-07
CN110200949A (zh) 2019-09-06
KR102177773B1 (ko) 2020-11-12
CY1120215T1 (el) 2018-12-12
UY34772A (es) 2013-11-29
EP3189830B1 (en) 2018-05-23
LT3278792T (lt) 2019-05-10
CA2871016A1 (en) 2013-11-07
US20150125525A1 (en) 2015-05-07
PE20150129A1 (es) 2015-02-13
HUE037702T2 (hu) 2018-09-28
KR102104070B1 (ko) 2020-04-24
JOP20200147A1 (ar) 2022-10-30
CN104302274A (zh) 2015-01-21
US20200214987A1 (en) 2020-07-09
PH12014502340A1 (en) 2014-12-22
TW202037370A (zh) 2020-10-16
TW201343202A (zh) 2013-11-01
PH12014502340B1 (en) 2014-12-22
US11534406B2 (en) 2022-12-27
CA3080035A1 (en) 2013-11-07
WO2013164315A1 (en) 2013-11-07
GEP201706736B (en) 2017-09-25
TN2014000441A1 (en) 2016-03-30
TWI618547B (zh) 2018-03-21
NO2659881T3 (tr) 2018-04-28
CO7141433A2 (es) 2014-12-12
TWI705833B (zh) 2020-10-01
DK2844220T3 (en) 2019-04-08
SA115370043B1 (ar) 2016-05-24
RS59697B1 (sr) 2020-01-31
CL2014002795A1 (es) 2015-02-13
JOP20200147B1 (ar) 2023-09-17
MY190392A (en) 2022-04-20
PT2844220T (pt) 2019-03-27
KR20150004910A (ko) 2015-01-13
MX2014012887A (es) 2015-05-08
BR112014026933B1 (pt) 2022-07-19
CY1121609T1 (el) 2020-05-29
EP3278792B1 (en) 2019-02-20
TR201809416T4 (tr) 2018-07-23
EP2659881B1 (en) 2017-11-29
HRP20180068T1 (hr) 2018-03-23
PL3278792T3 (pl) 2019-09-30
SI2844220T1 (sl) 2019-05-31
CA2871016C (en) 2023-03-21
TN2014000442A1 (en) 2016-03-30
US20170035698A1 (en) 2017-02-09
CA3052460A1 (en) 2013-11-07
AR090898A1 (es) 2014-12-17
ME03364B (me) 2019-10-20
ES2720258T3 (es) 2019-07-19
PT2844222T (pt) 2019-12-30
RS57431B1 (sr) 2018-09-28
BR112014026933A2 (pt) 2017-06-27
KR102198621B1 (ko) 2021-01-06
PL2844220T3 (pl) 2019-06-28
PL2659881T3 (pl) 2018-05-30
RS58625B1 (sr) 2019-05-31
CR20190246A (es) 2019-09-03
CN110200949B (zh) 2021-11-16
NZ629260A (en) 2017-01-27
TR201903569T4 (tr) 2019-04-22
ES2673931T3 (es) 2018-06-26
PH12014502339B1 (en) 2014-12-22
CA3052460C (en) 2022-06-07
US20140056980A1 (en) 2014-02-27
SA113340508B1 (ar) 2016-02-07
SI2659881T1 (en) 2018-03-30
ES2714448T3 (es) 2019-05-28
EP2844220B1 (en) 2019-01-23
GEP201706753B (en) 2017-10-25
CU24304B1 (es) 2018-01-10
DK3278792T3 (da) 2019-05-06
KR102102198B1 (ko) 2020-04-21
PH12014502339A1 (en) 2014-12-22
JOP20200144A1 (ar) 2017-06-16
HUE036187T2 (hu) 2018-06-28
JOP20200148B1 (ar) 2023-09-17
JOP20200145B1 (ar) 2023-09-17
EA201491781A1 (ru) 2014-12-30
PT3278792T (pt) 2019-05-23
EA032514B1 (ru) 2019-06-28
MX367127B (es) 2019-08-06
JOP20200146A1 (ar) 2022-10-30
EP3278792A1 (en) 2018-02-07
HUE042833T2 (hu) 2019-07-29
JOP20200146B1 (ar) 2023-09-17
KR20200073296A (ko) 2020-06-23
CL2014002796A1 (es) 2015-02-06
EP2844222B1 (en) 2019-11-13
PE20190625A1 (es) 2019-04-26
ME03641B (me) 2020-07-20
CN106983735A (zh) 2017-07-28
US11517534B2 (en) 2022-12-06
US10226430B2 (en) 2019-03-12
CN110237056A (zh) 2019-09-17
TW201720430A (zh) 2017-06-16
SI3278792T1 (sl) 2019-06-28
CN104271113A (zh) 2015-01-07
EP3187171A1 (en) 2017-07-05
AU2017210577A1 (en) 2017-08-24
MY169161A (en) 2019-02-19
ES2761341T3 (es) 2020-05-19
PL3189830T3 (pl) 2018-11-30
CO7151506A2 (es) 2014-12-29

Similar Documents

Publication Publication Date Title
TR201905226T4 (tr) Bir gecikmeli salım ilaç formülasyonu.
IL254501B (en) Online advertising with the possibility of payment in a social network
HK1208216A1 (en) Drug-conjugates, conjugation methods, and uses thereof
BR112014030278A2 (pt) anticorpo, e, composição.
EA201690780A1 (ru) Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
TR201907930T4 (tr) Bir sigara içim ürünü için tutuşturulabilir ısı kaynağı.
PL2877490T3 (pl) Inteiny podzielone, koniugaty i ich zastosowania
BR112015002738A2 (pt) composto , e , composição farmacêutica
BR112015010947A2 (pt) composições e métodos para aumentar o metabolismo energético.
HK1212625A1 (zh) 用於炎性疾病的抗- 、抗- 、抗- 、抗- 、抗- 和抗- 試劑
DK2834348T3 (da) 3d in vitro bifasisk brusk-knogle-konstruktion
PL2770836T3 (pl) Frormulacje, kompozycje i metabolity z Chromobacterium i ich zastsowanie
BR112014028921A2 (pt) injetor.
NL301064I2 (nl) toltrazuril en gleptoferron
PL2968139T3 (pl) Platforma miejscowego podania mikroemulsji
IL238978A0 (en) Social verification
TR201202948A2 (tr) Dapagliflozin ve uzatılmış salınımlı metaformin içeren tablet formülasyonu.
EP2879217A4 (en) FUEL CELL AND FUEL CELL STACK
BR112014000232A8 (pt) primeira composição, segunda composição e artigo
PH12015501390A1 (en) Tablets with improved acceptance and good storage stability
BR112014032501A2 (pt) composto, e, composição farmacêutica.
FR2996984B1 (fr) Support, notamment textile, biocide
FI20135208A (fi) Polttoaineinjektori
FR2980085B1 (fr) Article cosmetique, notamment faux-ongle
TH1401003508A (th) องค์ประกอบฆ่าพืชที่มีฟลูร์ออกซิไพร์และไกลโฟเซต